Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer
Key points are not available for this paper at this time.
Abstract
ClinicalTrials.gov Identifier: NCT02394795.
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer | Synapse